Bortezomib-based induction is often used in transplant-eligible patients with myeloma. The optimal peripheral blood stem cell (PBSC) mobilisation strategy in this context is unclear. We reviewed the efficacy of G-CSF alone (G-alone) vs. G-CSF and cyclophosphamide (G-cyclo: standard dose: 1.5-2 g/m 2 ; high dose: 3-4 g/m 2 ) PBSC mobilisation strategies in 288 patients who only received bortezomib, cyclophosphamide and dexamethasone (VCD) induction prior to autograft across six apheresis centres from November 2012 to June 2017. 'Uncomplicated successful mobilisation' was defined as achieving a PBSC yield of ≥4 × 10 6 /kg within two aphereses, without plerixafor or mobilisation-associated toxicity (predominantly febrile neutropenia, FN). Success rates were 84% in G-cyclo standard dose (6% FN), 64% in G-cyclo high dose (18% FN) and 69% in G-alone (plerixafor successfully salvaged 8/9 patients). Median total stem cell yield was significantly higher with G-cyclo, but not different between the two cyclophosphamide doses. Age greater than the median of 61 years was associated with higher failure rates (22 vs. 11%, p = 0.01) and lower PBSC yield, especially in the G-alone group. Prior radiotherapy exposure did not impact on collection success. Our observations suggest that both G-cyclo standard dose and G-alone are reasonable mobilisation strategies. The former may be preferred if salvage plerixafor is unavailable.
Introduction
Recent studies have confirmed that in eligible patients with newly diagnosed multiple myeloma (MM), autologous stem cell transplantation (ASCT) still offers superior progression free and overall survival in the era of novel induction regimens [1] . Optimising peripheral blood stem cells (PBSC) mobilisation after bortezomib-based induction is an important issue, but has not been clearly delineated as illustrated by variable practice both locally and globally. Both IMWG and Myeloma Foundation of Australia Medical and Scientific Advisory Group recommend the use of granulocyte-colony stimulating factor (G-CSF) alone (Galone) as the initial mobilisation regimen in patients with 'low risk' of failure, as defined by age <65 years and received fewer than four cycles of novel agent containing therapy [2, 3] . In contrast, the European experience predominantly comprised of chemo-mobilisation with G-CSF and cyclophosphamide (G-cyclo) with doses ranging from 1.5 to 4 g/m 2 or etoposide [4, 5] . Chemo-mobilisation is a strategy designed to increase PBSC yield, noting the addition of chemotherapy for mobilisation does not appear to provide additional anti-myeloma benefit prior to ASCT in the era of novel induction therapy [6] .
We undertook a multi-centre evaluation intending to compare the efficacy, toxicity and resource utilisation of PBSC mobilisation between G-alone and G-cyclo strategies in MM patients after receiving bortezomib-based induction therapy. Local heterogeneity of PBSC mobilisation in a uniform cohort of MM patients across multiple institutions gave us the opportunity to compare the outcomes of each approach.
Methods
We performed a multi-centre retrospective review of consecutive patients across six apheresis centres in Victoria, Australia who underwent PBSC mobilisation between November 2012 and March 2015, with extended data obtained from four of these centres up to June 2017. Patients were eligible for review if they had a diagnosis of previously untreated MM, received upfront bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy with or without radiotherapy prior to PBSC mobilisation and had a PBSC target yield of ≥4 × 10 9 /kg, the latter regarded as the minimal amount required to support two autografts [7, 8] . Ethics approval was obtained from the Human Research Ethics committees from all sites.
Induction with VCD was the standard of care for all newly diagnosed transplant-eligible MM patients at the treatment centres in this study during our study period. The chemotherapy protocol consisted of bortezomib 1.3 mg/m 2 intravenously or subcutaneously, administered either on days 1, 4, 8 and 11 as part of a 21-day cycle, or weekly (days 1, 8, 15 and 22) as part of a 28-day cycle in patients who did not require urgent cytoreduction, in combination with cyclophosphamide 300 mg/m 2 orally and dexamethasone 40 mg orally [9] . The administration schedule of the latter two components varied slightly between centres.
Patients were identified through the records of the apheresis units, MM and ASCT databases from the participating sites. Data collected included basic demographics, disease burden at diagnosis defined by degree of CD138 positive plasmacytosis on bone marrow trephine, induction chemotherapy details, prior radiotherapy exposure, disease status at time of mobilisation according to the International Myeloma Working Group (IMWG) definition [7] , white cell and platelet counts prior to mobilisation, mobilisation strategy used (including dose and schedule of G-CSF and/or cyclophosphamide, the latter divided into 'high' doses of 3-4 g/m 2 (G-cyclo high dose) and 'standard' doses of 1.5-2 g/m 2 (G-cyclo standard dose)), complications of mobilisation strategy, requirement for hospitalisation and outcomes of stem cell collection.
Four apheresis centres adopted a fixed protocol mobilisation approach for all-comers, whereas two centres utilised a mixture of both strategies in which certain clinicians preferred G-alone and others G-cyclo based on individual patient circumstances. The details of these strategies are summarised in the Results section below.
Comparison of mobilisation strategies evaluated included the peripheral blood (PB) CD34+ count (10 6 /L) on day one of apheresis, total stem cell CD34+ yield (10 6 /kg), stem cell CD34+ yield (10 6 /kg) after one session of apheresis, number of aphereses required to achieve target yield, number of patients achieving target PBSC yield, salvage strategies used including plerixafor [10] and toxicities such as unplanned hospitalisation and febrile neutropenia.
We defined a target yield of ≥4 × 10 9 /kg given that for most patients, the intention is to collect sufficient stem cells to support two ASCTs, either as planned upfront tandem transplants or as a second ASCT at relapse [2] . A successful mobilisation was defined as reaching this target after one or two aphereses, without plerixafor rescue. An uncomplicated successful mobilisation was defined as a successful mobilisation without any mobilisation-associated toxicity requiring hospitalisation. Poor mobilisers were defined as patients who did not undergo apheresis due to very low PB CD34 levels, those who underwent apheresis (often multiple) but did not achieve target of ≥4 × 10 9 /kg or those who required plerixafor rescue to achieve target during the first mobilisation attempt.
A limited costing analysis was performed to determine the average cost per mobilisation attempt per patient in our patient cohort. The following information was collected: medical procedures for vascular access, apheresis related costs, number of apheresis required, medications, day oncology admission (half a day for cyclophosphamide 1-2 g/m 2 and a full day for 3-4 g/m 2 ), laboratory testing, in vitro stem cell cryopreservation and hospital admission costs for febrile neutropenia. Medication costs included G-CSF (Nivestim), intravenous cyclophosphamide, mesna and plerixafor based on the Australian Pharmaceutical Benefits Schedule. Procedure related costs were obtained from the Australian Medicare Benefits Schedule. Admission costs were obtained from Clinical Costing (referenced to the Department of Health Victoria, Australia) based on an average cost of hospitalisation for febrile neutropenia with no significant complications, i.e. not requiring intensive care unit support, and the median days of hospital admission in our study population. The following cost estimates were used in the calculations based on Australian dollars: fixed mobilisation-related costs (excluding apheresis sessions) were A$889 for G-alone, A$2226 for G-cyclo standard dose and A$3434 for G-cyclo high dose, each day of apheresis cost A$1177, Plerixafor cost A$6991 per dose and an average uncomplicated 4-day hospital admission for febrile neutropenia cost A$5407. The cost of remobilisation was calculated based on remobilisation strategies used (Gcyclo standard dose, G-CSF and plerixafor, or G-alone) and the number of apheresis required to reach the target yield in our patient cohort. Of note, ten (6%) patients from the Galone group did not undergo a second mobilisation attempt. For the purpose of the cost analysis, we assumed that all ten patients were remobilised with G-cyclo standard dose (with a median of two apheresis sessions, as per the median number of apheresis required in the remobilised group), given that this was the most commonly used salvage regimen in our cohort.
Descriptive statistics are displayed as counts and percentage frequencies, median and range or interquartile range where appropriate to summarise our data. Comparisons between both groups were evaluated using χ 2 test or Fishers exact test for categorical data, and Mann-Whitney-U test for continuous variables. A two-tailed p-value of <0.05 was considered statistically significant. All analyses were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA). Table 1 outlines the baseline characteristics of the 288 eligible patients according to mobilisation approach. The median age was 61 years (range: 29-75 years) with male predominance (n = 183, 64%). Most patients achieved partial response or better at the time of mobilisation. No characteristic was significantly different between the Galone and G-cyclo groups.
Results

Patient characteristics
Mobilisation strategies
The G-alone strategy consisted of G-CSF 10 µg/kg administered once (n = 85) or twice daily (n = 16), or 5 µg/kg administered twice daily (n = 74) (Nivestim in 168 and Neupogen in 7). The median days of G-CSF administration including the morning of first apheresis day was 4 days (range: 4-7 days, median cumulative G-CSF dose of 40 µg/ kg), 5 days (range: 4-7 days, median cumulative G-CSF dose of 90 µg/kg) and 5 days (range: 4-6 days, median cumulative G-CSF dose of 45 µg/kg), respectively. Six (3%) patients did not undergo apheresis due to insufficient PB CD34+ counts.
G-cyclo mobilisation comprised of intravenous cyclophosphamide of varying doses administered on day 0: 1 g/ m 2 (n = 2), 1.5 g/m 2 (n = 41), 2 g/m 2 (n = 42), 3 g/m 2 (n = 6) and 4 g/m 2 (n = 22). Mesna (either intravenous or oral formulation) was administered to all patients who received doses of ≥2 g/m 2 . Accompanying G-CSF regimens consisted of filgrastim 5 µg/kg starting at day 5 (n = 25), 10 µg/ kg starting at day 2 (n = 50) (Nivestim in 73 patients and and Neupogen in 2) or single dose of pegfilgrastim (Neulasta) 12 mg administered on day 2 or 3 (n = 38). All patients in this group underwent apheresis. The median first day of apheresis was on day 11 (range: 8-18 days); 53 (47%) of patients underwent first apheresis on days 8 to 10, 38 (34%) on day 11, and 22 (19%) on day 12 or beyond.
Plerixafor was used as a rescue strategy according to physician discretion. During the study period, the Australian Pharmaceutical Benefits Scheme only reimbursed plerixafor use for G-cyclo mobilisation, thus limiting its use in the G-alone group. A single dose of plerixafor 240 µg/kg (if estimated GFR ≥50) or 160 µg/kg (if estimated GFR <50) up to a maximum dose of 24 mg was administered to 9 (5%) G-alone and 3 (3%) G-cyclo patients. Eight out of 9 (89%) G-alone and 2 out of 3 (67%) of G-cyclo patients were successfully rescued. The median PB CD34+ count prior to plerixafor use was 12 × 10 6 /L and 10 × 10 6 /L in the G-alone and G-cyclo group, respectively. Figure 1 and Table 2 summarise the overall outcomes of Galone compared with G-cyclo mobilisation. PBSC mobilisation with G-cyclo was more capable in achieving successful mobilisation, i.e. target yield of ≥4 × 10 6 /kg without requiring plerixafor and within two aphereses (88% vs. 69% with G-alone; p < 0.01). Additional apheresis procedures beyond two days, without plerixafor, secured successful collection to the target yield by an extra 9% in the G-alone group. G-cyclo produced significantly higher day 1 and total stem cell yield as well as fewer median apheresis sessions to achieve the target of ≥4 × 10 6 /kg. The use of rescue plerixafor successfully salvaged an additional 5% (n = 8) of G-alone and 2% (n = 2) of G-cyclo patients. Galone achieved a PBSC yield of ≥2 × 10 6 /kg in 87% of patients without plerixafor use and within two aphereses.
Stem cell collection
We then compared PBSC mobilisation outcomes between the different cyclophosphamide doses in the Gcyclo group, as well as G-CSF schedules in the G-alone group (Table 3 ). There were no significant differences in mobilisation outcomes between standard (1.5-2 g/m 2 ) and high doses (3-4 g/m 2 ) of cyclophosphamide. Comparison of G-CSF doses and schedule used for G-alone mobilisation revealed that G-CSF 5 µg/kg bd resulted in a significantly higher median total and day 1 PBSC yield (p < 0.01) with fewer apheresis sessions required compared with G-CSF 10 µg/kg once daily. A total G-CSF dose of 20 µg/kg/day resulted in a significantly higher median total and day 1 PBSC yield than a total dose of 10 µg/kg/day, noting however that the former cohort consisted of only 16 patients and was younger than the comparator group. The number of apheresis required to achieve ≥4 × 10 6 /kg G-CSF in the 20 µg/kg/day G-CSF group was less (median of 1 vs. 2 aphereses, p < 0.01).
Outcomes of PBSC collection (n =288):
target yield ≥4x106/kg Target not reached (n =30, 17%), including n =6 who did not undergo apheresis Radiotherapy was given to 20/175 (11%) of the G-alone and 14/113 (12%) of the G-cyclo patients prior to PBSC mobilisation. In the G-cyclo group, patients who have had prior radiotherapy had a significantly lower median total PBSC yield (5.6 vs. 9.6 × 10 6 /kg, p < 0.01) and a trend towards more apheresis sessions to achieve ≥4 × 10 6 /kg (median of 2 vs. 1, p = 0.07) and higher failure rates (14 vs. 4%, p = 0.11). This finding was irrespective of radiotherapy sites, although the majority (71%) of the group had pelvic and/or spine radiotherapy. In contrast, there were no significant differences identified between patients with and without prior radiotherapy in the G-alone group.
Complications
Twelve (11%) patients from the G-cyclo group had complications requiring hospitalisation during the mobilisation. Of these, 10 (9%) were due to febrile neutropenia, and one each for lower back pain and severe mucositis with neutropenia. The median number of days of hospitalisation was 4 days (range: 1-9 days). There were no intensive care admissions or deaths. Higher doses of cyclophosphamide were associated with an increased rate of febrile neutropenia: 5/28 (18%) in 3-4 g/m 2 group vs. 5/85 (6%) in the 1-2 g/m 2 group (p = 0.05). There was a trend towards a higher rate of febrile neutropenia with older age (≤61 vs. >61 years, 3/63 (5%) vs. 7/50 (14%), p = 0.09). Specifically, the incidence of febrile neutropenia was 14% (2/14) in patients age ≤61 years compared with 21% (3/14) in age >61 years in patients receiving G-cyclo high dose, and 1/49 (2%) in patients age ≤61 years vs. 11% (4/36) in age >61 years in those receiving G-cyclo standard dose. No patient from the G-alone group was hospitalised for complications.
Poor mobilisers
Forty-six (16%) patients fulfilled the criteria for being poor mobilisers. Factors on univariate analysis associated with poor mobilisation included mobilisation by G-alone (p < 0.01) and older age. In patients with age greater than the median age of the study cohort (61 years; n = 138), there was a higher failure rate (22 vs. 11%, p = 0.01) with a lower day 1 (p < 0.01) and total PBSC yield (p < 0.01) compared with patients age 61 years or less. When stratified by mobilisation strategy, the significant correlation between age and outcomes were only retained in the G-alone group with a significant higher failure rate (28 vs. 15%, p = 0.03) in older patients. The G-cyclo group did not have significant correlation between age >61 years and failure rates (10 vs. 5%, p = 0.47), day 1 (p = 0.10) and total PBSC yield (p = 0.59). Premobilisation platelet counts were significantly lower in the poor mobilisers (median platelet count of 191 vs. 225 × 10 9 /L, p = 0.004). However, we could not identify a platelet count which predicted poor mobilisation, with a count of <150 × 10 9 /L seen in 13% and 11% of poor and successful mobilisers, respectively. There were no significant associations found between poor mobilisers and gender, prior radiotherapy, number of bortezomib doses prior to mobilisation, premobilisation disease status or white cell count. Uncomplicated successful mobilisation Table 4 shows successful mobilisation and uncomplicated successful mobilisation rates according to mobilisation strategies. Successful mobilisation was significantly higher in both G-cyclo groups vs. G-alone, whilst uncomplicated successful mobilisation was only significantly higher in the G-cyclo standard dose group due to the higher rate of febrile neutropenia in the G-cyclo high dose group.
Cost of mobilisation
The average cost per first mobilisation attempt per patient in our patient cohort was calculated to be approximately A $3086 for G-alone, A$4415 for standard dose G-cyclo and A$6229 for high dose G-cyclo. When factoring in costs for remobilisation attempts, the average total cost per patient in our cohort was estimated to be approximately A$3932 for G-alone, A$4454 for standard dose G-cyclo, and A$6268 for high dose G-cyclo.
Discussion
It is important to acknowledge that in this study we used novel criteria to define success and failure, based on what we regarded as clinically relevant. Using these criteria, we observed that in our cohort successful mobilisation was associated with G-cyclo strategy and younger age of ≤61 years. The overall benefit was most apparent using standard doses of cyclophosphamide (1.5-2 g/m 2 ) with a much lower incidence of complications compared with higher cyclophosphamide doses and at a cost comparable with G-alone mobilisation. Based on our data, the number of patients needed to be treated with G-cyclo standard dose to prevent the use of salvage therapy in a G-only patient was 1 in 5.
Published schedules of G-alone mobilisation in ASCT mobilisation are limited and varied, with G-CSF 10 µg/kg/ daily being the most widely used schedule [11, 12] . We observed that the 5 µg/kg/bd schedule appear to be slightly superior to the 10 µg/kg/d schedule despite the same total daily dose. The reason for this difference was not immediately apparent, as these schedules have been compared in stem cell mobilisation of healthy donors without significant difference in efficacy [13, 14] . We speculate that the superiority of the twice daily dose may represent a pharmacokinetic effect rather than a cumulative dose effect, which was minimally different. We also note that G-CSF10 µg/kg administered twice daily resulted in a better yield with no reported failures in our cohort, though it was in a small group of younger patients. Higher doses of G-CSF may be a consideration in patients deemed at risk of mobilisation failure in future studies. was not included due to small numbers (n = 2).
Stem cell mobilisation post VCD induction in myeloma...
Our findings are comparable to a smaller retrospective study comparing PBSC mobilisation with G-alone vs. Gcyclo (uniformly 3 g/m 2 ) in a similar cohort of patients, which observed higher PBSC yield and lower median apheresis days in the G-cyclo group, albeit with 16% experiencing febrile neutropenia [15] . Other retrospective studies have suggested increased total PBSC yield, lower mobilisation failure rates and possibly fewer apheresis sessions with chemotherapy priming compared with cytokine-alone mobilisation, with the offset of a 14-30% risk of neutropenic sepsis and hospitalisation with cyclophosphamide doses of more than 3 g/m 2 [7, [16] [17] [18] . In our experience, higher doses (≥3 g/m 2 ) of cyclophosphamide did not increase PBSC yield compared with lower doses and were associated with a higher risk of febrile neutropenia and a significantly higher cost.
We identified older age (greater than the median of 61 years in this study) as a significant factor impacting on mobilisation outcomes. Our findings suggest that G-cyclo may be the more potent regimen capable of overcoming age as a factor when compared with G-alone, with a modest risk of febrile neutropenia. Studies have also reported extensive radiotherapy exposure as another risk factor of poor mobilisation [19] . In our experience, prior radiotherapy was associated with lower stem cell yields in the G-cyclo group but not in the G-alone cohort. This may be a true phenomenon but may also be due to the heterogeneity of radiotherapy exposure and the small patient numbers in each cohort.
In summary, our observations may be useful in determining the optimal mobilisation strategy after bortezomibbased induction in patients with MM. G-cyclo strategy administered at standard doses of 1.5-2 g/m 2 appeared to be a more efficient strategy and cost comparable in achieving a target PBSC yield of ≥4 × 10 6 /kg when compared to Galone, but with the downside of additional chemotherapy exposure (without anti-myeloma benefit) and a modest risk of febrile neutropenia. G-alone, preferably with a twice daily administration schedule, was nonetheless capable of efficiently and safely achieving target yields in the majority of patients, especially if the option of salvage plerixafor is available. Whether subsets of patients can be pre-identified, using factors such as extent of prior radiotherapy, premobilisation platelet count and age as benefiting from a specific strategy will require further large prospective studies. 
